Form 8-K - Current report:
SEC Accession No. 0001628280-25-034132
Filing Date
2025-07-03
Accepted
2025-07-03 08:49:21
Documents
15
Period of Report
2025-06-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ardx-20250630.htm   iXBRL 8-K 29169
2 EX-10.1 ardx-20250703xexx101.htm EX-10.1 511278
7 ardx-20250630_g1.jpg GRAPHIC 2570
  Complete submission text file 0001628280-25-034132.txt   793744

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ardx-20250630.xsd EX-101.SCH 2036
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ardx-20250630_def.xml EX-101.DEF 15269
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ardx-20250630_lab.xml EX-101.LAB 26929
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ardx-20250630_pre.xml EX-101.PRE 15971
18 EXTRACTED XBRL INSTANCE DOCUMENT ardx-20250630_htm.xml XML 3294
Mailing Address 34175 ARDENWOOD BLVD. FREMONT CA 94555
Business Address 34175 ARDENWOOD BLVD. FREMONT CA 94555 510-745-7047
ARDELYX, INC. (Filer) CIK: 0001437402 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36485 | Film No.: 251103869
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)